
Bavarian Nordic
BAVA · CO · Healthcare / Biotechnology
Price History
Full chartMarket Stats
About
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV, that is in phase 2 trial for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, England, Finland, Switzerland, Japan, Austria, Italy, Spain, Taiwan, Saudi Arabia, Australia, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
Company Details
- SectorHealthcare
- IndustryBiotechnology
- CEODr. Paul John Chaplin MSc, Ph.D.
- Employees1.91K
- HeadquartersPhilip Heymans Alle 3, Hellerup, Denmark, 2900, Denmark
- Websitehttps://www.bavarian-nordic.com
Leadership
- Dr. Paul John Chaplin MSc, Ph.D.CEO & President · b. 1967
- Mr. Henrik Juuel M.Sc.CFO & Executive VP · b. 1965
- Mr. Russell Thirsk M.Sc.Executive VP & COO · b. 1968
- Mr. Rolf Sass SorensenVice President of Investor Relations
- Ms. Nicole SeroffVice President Corporate Communications
- Mr. Jean-Christophe May M.B.A., Pharm.D.Executive VP & Chief Commercial Officer · b. 1967
Financials
Income Statement
Balance Sheet
Cash Flow
Earnings
Key Statistics & Ratios
Stock Splits
- Mar 10, 2020694:549
- May 6, 201149:38
- Jan 13, 201019:16
- Mar 7, 2007321:304
- Jun 1, 20051495:1376
- Jun 3, 200224:23
- May 28, 2001110:107